Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890402021> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2890402021 endingPage "4018" @default.
- W2890402021 startingPage "4018" @default.
- W2890402021 abstract "4018 Background: TACE is often used to treat unresectable HCC (uHCC). However, there is no globally accepted consensus on the indication and definition of TACE failure. It is critical to reassess the risk/benefit of continuing TACE after failure as it may delay or prevent pts from receiving subsequent treatments. Methods: OPTIMIS, an international, prospective, observational study, enrolled pts with uHCC for whom a decision to treat with TACE was made at study entry. Practice patterns, safety, subsequent treatments, and outcomes data were collected. TACE ineligibility was defined and consistent with international and regional guidelines. Data were analyzed using descriptive statistical methods. Results: Overall, 1650 pts received TACE; 529 pts (32%) were BCLC stage C, 118 (7%) had extrahepatic spread, and 123 (7%) had portal vein thrombosis. At inclusion visit, 636 pts (39%) received TACE despite being TACE ineligible according to protocol-specified criteria. After first TACE, the proportion of pts with chronic liver function deterioration (worsening in CTCAE grade 30–90 days post TACE) ranged from 11% to 29% across assessed liver parameters. Complete and partial response rates to first TACE (N=1650) were 14% and 26%, respectively, which decreased by second (10% and 16%; n=1002), third (10% and 15%; n=580), and fourth (8% and 17%; n=338) TACE. Progressive disease rate increased by number of TACE procedures: 18%, 21%, 25%, and 27% for first, second, third, and fourth TACE, respectively. In total, only 507 pts (31%) became TACE ineligible during the study. Of those 507 pts, 47 (9%) received sorafenib at the time of TACE ineligibility and 460 (91%) received sorafenib later or not at all. Considerable imbalances between the 2 cohorts were observed; a propensity score analysis is planned to analyze overall survival from TACE ineligibility. Conclusions: These results indicate that real-world TACE use appears to deviate from treatment guidelines. This heterogeneity highlights the need for a globally accepted consensus on the indication and definition of TACE failure. These observations also indicate the importance of monitoring liver function in pts receiving TACE. Clinical trial information: NCT01933945." @default.
- W2890402021 created "2018-09-27" @default.
- W2890402021 creator A5010240694 @default.
- W2890402021 creator A5016315141 @default.
- W2890402021 creator A5018105181 @default.
- W2890402021 creator A5019510003 @default.
- W2890402021 creator A5029171331 @default.
- W2890402021 creator A5032900701 @default.
- W2890402021 creator A5064387329 @default.
- W2890402021 creator A5067969237 @default.
- W2890402021 creator A5069831074 @default.
- W2890402021 creator A5073880705 @default.
- W2890402021 creator A5083613070 @default.
- W2890402021 creator A5088900806 @default.
- W2890402021 date "2018-05-20" @default.
- W2890402021 modified "2023-10-15" @default.
- W2890402021 title "Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis." @default.
- W2890402021 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.4018" @default.
- W2890402021 hasPublicationYear "2018" @default.
- W2890402021 type Work @default.
- W2890402021 sameAs 2890402021 @default.
- W2890402021 citedByCount "55" @default.
- W2890402021 countsByYear W28904020212018 @default.
- W2890402021 countsByYear W28904020212019 @default.
- W2890402021 countsByYear W28904020212020 @default.
- W2890402021 countsByYear W28904020212021 @default.
- W2890402021 countsByYear W28904020212022 @default.
- W2890402021 countsByYear W28904020212023 @default.
- W2890402021 crossrefType "journal-article" @default.
- W2890402021 hasAuthorship W2890402021A5010240694 @default.
- W2890402021 hasAuthorship W2890402021A5016315141 @default.
- W2890402021 hasAuthorship W2890402021A5018105181 @default.
- W2890402021 hasAuthorship W2890402021A5019510003 @default.
- W2890402021 hasAuthorship W2890402021A5029171331 @default.
- W2890402021 hasAuthorship W2890402021A5032900701 @default.
- W2890402021 hasAuthorship W2890402021A5064387329 @default.
- W2890402021 hasAuthorship W2890402021A5067969237 @default.
- W2890402021 hasAuthorship W2890402021A5069831074 @default.
- W2890402021 hasAuthorship W2890402021A5073880705 @default.
- W2890402021 hasAuthorship W2890402021A5083613070 @default.
- W2890402021 hasAuthorship W2890402021A5088900806 @default.
- W2890402021 hasConcept C126322002 @default.
- W2890402021 hasConcept C141071460 @default.
- W2890402021 hasConcept C23131810 @default.
- W2890402021 hasConcept C2777075537 @default.
- W2890402021 hasConcept C2777377203 @default.
- W2890402021 hasConcept C2778019345 @default.
- W2890402021 hasConcept C2778695046 @default.
- W2890402021 hasConcept C2778800853 @default.
- W2890402021 hasConcept C2778902805 @default.
- W2890402021 hasConcept C2780868729 @default.
- W2890402021 hasConcept C2992208098 @default.
- W2890402021 hasConcept C71924100 @default.
- W2890402021 hasConcept C90924648 @default.
- W2890402021 hasConceptScore W2890402021C126322002 @default.
- W2890402021 hasConceptScore W2890402021C141071460 @default.
- W2890402021 hasConceptScore W2890402021C23131810 @default.
- W2890402021 hasConceptScore W2890402021C2777075537 @default.
- W2890402021 hasConceptScore W2890402021C2777377203 @default.
- W2890402021 hasConceptScore W2890402021C2778019345 @default.
- W2890402021 hasConceptScore W2890402021C2778695046 @default.
- W2890402021 hasConceptScore W2890402021C2778800853 @default.
- W2890402021 hasConceptScore W2890402021C2778902805 @default.
- W2890402021 hasConceptScore W2890402021C2780868729 @default.
- W2890402021 hasConceptScore W2890402021C2992208098 @default.
- W2890402021 hasConceptScore W2890402021C71924100 @default.
- W2890402021 hasConceptScore W2890402021C90924648 @default.
- W2890402021 hasIssue "15_suppl" @default.
- W2890402021 hasLocation W28904020211 @default.
- W2890402021 hasOpenAccess W2890402021 @default.
- W2890402021 hasPrimaryLocation W28904020211 @default.
- W2890402021 hasRelatedWork W1566214443 @default.
- W2890402021 hasRelatedWork W2047608762 @default.
- W2890402021 hasRelatedWork W2376016508 @default.
- W2890402021 hasRelatedWork W2471901561 @default.
- W2890402021 hasRelatedWork W2785875853 @default.
- W2890402021 hasRelatedWork W2889832490 @default.
- W2890402021 hasRelatedWork W3027742624 @default.
- W2890402021 hasRelatedWork W3092021409 @default.
- W2890402021 hasRelatedWork W3203016989 @default.
- W2890402021 hasRelatedWork W65397546 @default.
- W2890402021 hasVolume "36" @default.
- W2890402021 isParatext "false" @default.
- W2890402021 isRetracted "false" @default.
- W2890402021 magId "2890402021" @default.
- W2890402021 workType "article" @default.